Harmony Biosciences Holdings (HRMY)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$33.11

+0.64 (+1.97%)

Market Cap: $1.91B

Last updated: Nov 06, 2026 at 4:10 PM ET

Earnings

Performance (10Y)

Beat Rate

68%(17/25)

Avg Surprise

+212.11%

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$1.67

Range$1.58 - $1.76

2 analysts

Revenue Consensus

$281M

Range$255M - $293M

12 analysts

Last 12 of 26 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$1.67	$1.58 - $1.76	-	-	2	-	-
Sep 30, 2026Sep 26 Reported Nov 4, 2026Reported Nov 4	$0.81	$1.00	$0.94 - $1.06	-19.00%	Miss	2	3 0 30d	-25.0%
Jun 30, 2026Jun 26 Reported Aug 4, 2026Reported Aug 4	$1.28	$0.97	$0.83 - $1.09	+31.96%	Beat	3	1 1 30d	+39.1%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$0.79	$0.93	$0.67 - $1.22	-15.05%	Miss	5	0 2 30d	+1.5%
Dec 31, 2025Dec 25 Reported Feb 24, 2026Reported Feb 24	$0.57	$0.86	$0.73 - $0.93	-33.72%	Miss	4	2 0 30d	-47.2%
Sep 30, 2025Sep 25 Reported Nov 4, 2025Reported Nov 4	$1.08	$0.86	$0.81 - $0.91	+25.58%	Beat	2	1 0 30d	+4.9%
Jun 30, 2025Jun 25 Reported Aug 5, 2025Reported Aug 5	$0.92	$0.96	$0.85 - $1.11	-4.17%	Miss	4	2 1 30d	-12.4%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$0.78	$0.91	$0.77 - $1.45	-14.79%	Miss	3	0 1 30d	-11.5%
Dec 31, 2024Dec 24 Reported Feb 25, 2025Reported Feb 25	$1.08	$0.82	$0.77 - $0.90	+31.71%	Beat	4	1 0 30d	+140.0%
Sep 30, 2024Sep 24 Reported Oct 29, 2024Reported Oct 29	$1.03	$0.88	$0.67 - $0.97	+17.05%	Beat	8	0 1 30d	+6.2%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$1.05	$0.12	$-0.08 - $0.20	+775.00%	Beat	6	0 2 30d	+38.2%
Mar 31, 2024Mar 24 Reported Apr 30, 2024Reported Apr 30	$0.88	$0.69	$0.58 - $0.77	+27.54%	Beat	7	1 1 30d	+33.3%
Dec 31, 2023Dec 23 Reported Feb 22, 2024Reported Feb 22	$0.45	$0.48	$0.04 - $0.83	-6.25%	Miss	8	1 1 30d	-43.0%

Key Metrics

Valuation
P/E Ratio	9.60	EV/EBITDA	5.94x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	18.00%	Operating Margin	20.20%
ROE	18.70%	ROIC	13.73%
Financial Health
Debt/Equity	0.14x	Interest Coverage	16.95x
Current Ratio	3.44x	Quick Ratio	3.42x
Trading Statistics
Beta	0.98	Avg Volume	1.19M
52-Week High	$43.49	52-Week Low	$25.90

Technical Indicators Dashboard

Moving Averages

SMA 10$36.56

SMA 20$37.06

SMA 50$39.36

SMA 200$34.66

EMA 10$35.77

EMA 20$36.92

EMA 50$38.01

EMA 200$36.03

MACD

Line: -1.28Signal: -0.82Hist: -0.46

ADX

ADX: 31.9+DI: 10.6-DI: 34.7

Aroon & PSAR

Aroon Up4.0

Aroon Down100.0

PSAR$39.21

Bollinger Bands

Upper Band$40.70

Lower Band$33.43

%B Position1962%(Upper)

Band Width-0.04

RSI (14-Day)

Neutral

30.9

Momentum Oscillators

Stoch %K13.1

Stoch %D29.7

Williams %R-88.6

ROC (10d)-8.4%

Momentum-3.02

CCI (20d)-219.4

MFI (14d)28.4

Volatility Measures

ATR (14d)$1.83(5.5%)

StdDev (20d)1.82

Hist Vol49.3%(High)

Volume Flow

VWAP$32.92

OBV-2.7M

AD Line7.7M

CMF (20d)-0.104

Volume Metrics

Avg Vol (20d)1.2M

Vol Ratio0.6x

VWMA (20d)$36.67

Pivot Points

R3$38.05

R2$36.86

R1$34.67

Pivot Point$33.48

S1$31.29

S2$30.10

S3$27.91

Advanced Oscillators

TSI-24.57

Ultimate Osc36.9

KST-84.40

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$268.92M	$261.28M	$215.39M	$243.78M	$239.46M	$200.49M	$184.73M	$201.27M	$186.04M	$172.81M	$154.62M	$168.41M
Cost of Revenue	$80.69M	$63.20M	$44.51M	$68.55M	$59.65M	$38.15M	$31.99M	$54.41M	$42.78M	$32.14M	$27.48M	$43.15M
Gross Profit	$188.23M	$198.08M	$170.88M	$175.23M	$179.81M	$162.34M	$152.74M	$146.86M	$143.26M	$140.67M	$127.13M	$125.26M

Operating Expenses	$134.03M	$108.77M	$133.58M	$136.67M	$114.32M	$114.16M	$96.49M	$91.13M	$81.55M	$119.31M	$75.10M	$85.06M
R&D	$71.66M	$46.60M	$69.38M	$49.93M	$54.96M	$50.16M	$34.54M	$34.67M	$25.39M	$63.58M	$22.19M	$30.31M
SG&A	$27.65M	$28.05M	$32.51M	$57.56M	$29.81M	$33.92M	$31.24M	$28.86M	$28.59M	$27.22M	$25.68M	$27.87M
Operating Income	$54.20M	$89.32M	$37.29M	$38.56M	$65.49M	$48.18M	$56.24M	$55.73M	$61.71M	$21.36M	$52.03M	$40.20M

Interest Income	$8.43M	$7.07M	$5.76M	$5.85M	$5.73M	$5.30M	$5.04M	$4.48M	$4.93M	$4.71M	$4.43M	$4.10M
Interest Expense	$3.06M	$3.07M	$3.23M	$3.55M	$3.62M	$3.65M	$3.84M	$4.21M	$4.35M	$4.40M	$4.54M	$4.80M
Income Before Tax	$59.25M	$93.27M	$39.69M	$40.76M	$67.49M	$49.64M	$57.18M	$56.16M	$62.17M	$21.69M	$51.78M	$39.69M
Income Tax Expense	$11.05M	$17.83M	$7.20M	$18.27M	$16.63M	$9.86M	$11.62M	$6.68M	$16.08M	$10.10M	$13.45M	$13.08M

Net Income	$48.20M	$75.43M	$32.49M	$22.49M	$50.87M	$39.78M	$45.56M	$49.48M	$46.09M	$11.59M	$38.33M	$26.61M

EBITDA	$59.28M	$94.96M	$43.06M	$44.29M	$71.17M	$53.66M	$61.65M	$61.53M	$67.18M	$27.00M	$57.60M	$45.85M
EBIT	$53.88M	$89.26M	$37.16M	$38.45M	$65.38M	$47.99M	$55.97M	$55.89M	$61.59M	$21.39M	$51.89M	$40.39M

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about HRMY

Government Contracts

Gov Obligations (TTM)

$614408

Gov Obligations / Revenue

0.1%

Obligations YoY

N/A

Active Awards

New Awards (TTM)

Avg Remaining Term

N/A

Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
36C26026F0062	Department of Veterans AffairsDepartment of Veterans Affairs	$635245	Dec 1, 2025	Jun 30, 2026	BULK - WAKIX 17.8MG TAB
36C24526N0090	Department of Veterans AffairsDepartment of Veterans Affairs	$10418	Oct 7, 2025	Oct 10, 2025	WAKIX 17.8 MG
36C24526N0088	Department of Veterans AffairsDepartment of Veterans Affairs	$10418	Oct 2, 2025	Oct 7, 2025	WAKIX 17.8 MG

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Sep 30, 2026.

News

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences (HRMY) reported Q3 2026 earnings of 81 cents per share, missing the Zacks Consensus Estimate of $1.00 due to higher research and development expenses and milestone charges. Despite the earnings miss...

TradingView•Nov 5, 2026 12:42 PM ET11/5/26•Somewhat-Bearish

Earnings call transcript: Harmony Biosciences misses Q3 2026 profit view

Harmony Biosciences reported Q3 2026 earnings per share of $0.81, missing the $1.11 forecast, and revenue of $268.9 million...

Investing.com•Nov 5, 2026 10:53 AM ET11/5/26•Somewhat-Bearish

Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming

Harmony Biosciences reported a third-quarter miss primarily due to increased royalty costs and decelerating growth of its WAKIX franchise, rather than a drop in demand. While patient additions remained steady...

Finviz•Nov 4, 2026 1:40 PM ET11/4/26•Bearish

Harmony Biosciences Q3 Earnings Call Highlights

Harmony Biosciences reported strong Q3 net revenue of $269 million, driven by continued demand for its narcolepsy treatment, WAKIX...

TradingView•Nov 4, 2026 1:11 PM ET11/4/26•Bullish

Harmony Biosciences Plans CEO Transition for 2027

Harmony Biosciences has announced a leadership transition, with Peter Anastasiou set to become president, CEO, and board member on January 1, 2027. Current CEO Jeffrey M. Dayno, MD...

Sleep Review•Nov 4, 2026 12:40 PM ET11/4/26•Somewhat-Bullish

HRMY Valuation and Fair Value

P/E: 9.6x
Forward P/E: 8.6x
EV/EBITDA: 5.9x
P/B: 1.8x

See GNG's fair value

HRMY Profitability: Margins, ROIC and FCF

Gross margin: 74.0%
Operating margin: 20.2%
Net margin: 18.0%
ROIC: 13.7%
ROE: 18.7%
FCF margin: 32.6%

HRMY Competitors

Company	Ticker
LeMaitre Vascular Inc	LMAT
Replimune Group Inc	REPL
GeneDx Holdings Corp.	WGS
BioLife Solutions Inc	BLFS
Inspire Medical Systems Inc	INSP
Vir Biotechnology Inc	VIR
Veracyte Inc	VCYT
Certara Inc	CERT

Sector: Healthcare

HRMY Analyst Ratings

Consensus: Buy
Analysts: 11
Strong Buy: 2
Buy: 5
Hold: 3
Sell: 0
Strong Sell: 1

HRMY Bull Case vs Bear Case

Bull case

HRMY converts 32.6% of revenue into free cash flow.
HRMY grew quarterly revenue 12.3% year over year.
63.6% of HRMY's analyst ratings are Buy or Strong Buy.

Bear case

HRMY beat EPS estimates in 37.5% of its last 8 reported quarters.

HRMY Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: 0.3%
EPS estimate (fiscal period ending Dec 31, 2026): $1.67

HRMY Earnings Call

The latest HRMY earnings call transcript on file is labeled 2026Q3.

Read the 2026Q3 transcript

HRMY ETF Holders

GNG tracks 13 ETFs that hold HRMY. The largest weights:

State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.86% of the fund
VictoryShares Small Cap Free Cash Flow ETF (SFLO), 0.76% of the fund
Avantis U.S. Small Cap Value ETF (AVUV), 0.34% of the fund
iShares Core S&P Small-Cap ETF (IJR), 0.11% of the fund
Royce Value Trust Inc (RVT), 0.10% of the fund

Open the ETF Stock Exposure tool for HRMY

See insider activity

Frequently Asked Questions About HRMY

Does HRMY pay dividends?

Harmony Biosciences Holdings (HRMY) does not currently pay a regular dividend.

What is HRMY's P/E ratio?

Harmony Biosciences Holdings has a price-to-earnings (P/E) ratio of 9.60.

What is HRMY's market cap?

Harmony Biosciences Holdings (HRMY) has a market capitalization of $1.91B with a current stock price of $33.11.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In